CHEK2
<div class="infobox infobox-gene">
<span class="infobox-title">CHEK2</span>
<table>
<tr><th>Full Name</th><td>Checkpoint Kinase 2</td></tr>
<tr><th>Chromosomal Location</th><td>22q12.1</td></tr>
<tr><th>NCBI Gene ID</th><td>1111</td></tr>
<tr><th>OMIM</th><td>604373</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000149554</td></tr>
<tr><th>UniProt ID</th><td>O96017</td></tr>
<tr><th>Protein</th><td>CHEK2 protein</td></tr>
<tr><th>Associated Diseases</th><td>Li-Fraumeni syndrome variant, Prostate cancer, Breast cancer, Osteosarcoma, Glioma</td></tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
Checkpoint kinase 2 (CHEK2) is a serine/threonine-protein kinase encoded by the CHEK2 gene located on chromosome 22q12.1[@ahn2000]. CHEK2 plays a critical role in maintaining genomic stability through its involvement in the DNA damage checkpoint pathway. As a key effector of ATM-mediated DNA damage response, CHEK2 helps coordinate cell cycle arrest, DNA repair, and [apoptosis](/entities/apoptosis) in response to genotoxic stress["@matsuoka2000"].
Mutations in CHEK2 have been associated with increased cancer risk, particularly in the context of Li-Fraumeni-like syndromes. The protein's kinase activity is regulated by phosphorylation in response to DNA double-strand breaks, making it a potential therapeutic target in cancers with defective DNA repair mechanisms.
Function
<div class="infobox infobox-gene">
<span class="infobox-title">CHEK2</span>
<table>
<tr><th>Full Name</th><td>Checkpoint Kinase 2</td></tr>
<tr><th>Chromosomal Location</th><td>22q12.1</td></tr>
<tr><th>NCBI Gene ID</th><td>1111</td></tr>
<tr><th>OMIM</th><td>604373</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000149554</td></tr>
<tr><th>UniProt ID</th><td>O96017</td></tr>
<tr><th>Protein</th><td>CHEK2 protein</td></tr>
<tr><th>Associated Diseases</th><td>Li-Fraumeni syndrome variant, Prostate cancer, Breast cancer, Osteosarcoma, Glioma</td></tr>
</table>
</div>
Function
Checkpoint kinase 2 (CHEK2) is a serine/threonine-protein kinase that plays a critical role in the DNA damage checkpoint pathway[@ahn2000]. In response to DNA double-strand breaks (DSBs), ATM kinase phosphorylates CHEK2 at Thr68, activating its kinase activity[@matsuoka2000]. Activated CHEK2 then phosphorylates multiple downstream targets including:
- p53 (TP53): Phosphorylation at Ser20 disrupts MDM2-mediated degradation, stabilizing p53 and promoting DNA repair or apoptosis[@chehab2000]
- CDC25A/B/C: Phosphorylation leads to cell cycle arrest at G1/S and G2/M checkpoints[@zhou2004]
- BRCA1: Phosphorylation supports homologous recombination repair[@zhang2003]
- E2F1: Phosphorylation regulates transcription of pro-apoptotic genes[@stevens2003]
CHEK2 exists as a dimer that undergoes trans-autophosphorylation upon DNA damage[@cai2009]. The protein contains an N-terminal SQ/TQ cluster domain (SCD) with multiple ATM phosphorylation sites, a central forkhead-associated (FHA) domain, and a C-terminal kinase domain[@li2002].
Disease Associations
Cancer
- Li-Fraumeni syndrome: Heterozygous germline CHEK2*1100delC variant increases cancer risk 2-4 fold[@weischer2008]
- Prostate cancer: CHEK2 variants associated with aggressive disease[@seppala2003]
- Breast cancer: CHEK2 I157T variant increases risk 1.5-2 fold[@bane2007]
Neurodegeneration
- Alzheimer's disease: CHEK2 dysregulation reported in AD brain tissue; involved in neuronal DNA damage response[@hashimoto2002]
- [Parkinson's disease](/diseases/parkinsons-disease): CHEK2 phosphorylation patterns altered in PD models[@jhaveri2013]
- Amyotrophic lateral sclerosis (ALS): CHEK2 activation observed in ALS patient spinal cord[@sathasivam2014]
Expression
CHEK2 is ubiquitously expressed in human tissues with highest levels in testis, thymus, and prostate[@us]. In the brain, CHEK2 is expressed in:
- [Neurons](/entities/neurons) (cortical, hippocampal, cerebellar)[@inoue2002]
- [Astrocytes](/entities/astrocytes)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Oligodendrocytes](/cell-types/oligodendrocytes)
Expression increases in response to DNA damage, oxidative stress, and during aging[@rashielkeles2011].
Therapeutic Implications
- CHEK2 inhibitors: Preclinical compounds in development for cancer therapy[@antoni2007]
- DNA damage response modulators: Combination strategies with radiotherapy or chemotherapy[@zhou2014]
See Also
- [ATM](/genes/atm) - ATM kinase, upstream activator of CHEK2
- [p53](/mechanisms/p53-pathway) - Tumor suppressor, downstream target
- [DNA Damage Response](/mechanisms/dna-damage-response) - Broader pathway context
- [BRCA1](/genes/brca1) - DNA repair partner
- [Alzheimer's Disease](/diseases/alzheimers-disease) - Disease association
External Links
- [NCBI Gene: CHEK2](https://www.ncbi.nlm.nih.gov/gene/1111)
- [UniProt: O96017](https://www.uniprot.org/uniprot/O96017)
- [OMIM: 604373](https://www.omim.org/entry/604373)
References
[Ahn J, et al, Human CHK2 protein kinase (2000)](https://pubmed.ncbi.nlm.nih.gov/10835412/)
[Matsuoka S, et al, ATM and CHK2 target network (2000)](https://pubmed.ncbi.nlm.nih.gov/11062257/)
[Chehab NH, et al, Chk2/hCds1 functions as a DNA damage checkpoint (2000)](https://pubmed.ncbi.nlm.nih.gov/10625657/)
[Zhou BB, Bartek J, Targeting the checkpoint kinases (2004)](https://pubmed.ncbi.nlm.nih.gov/15582248/)
[Zhang J, et al, BRCA1 regulates CHK2 (2003)](https://pubmed.ncbi.nlm.nih.gov/14597757/)
[Stevens C, et al, E2F1 phosphorylation by CHK2 (2003)](https://pubmed.ncbi.nlm.nih.gov/14681206/)
[Cai Z, et al, Dimerization of CHK2 (2009)](https://pubmed.ncbi.nlm.nih.gov/19188257/)
[Li J, et al, Structure of human CHK2 (2002)](https://pubmed.ncbi.nlm.nih.gov/11877377/)
[Weischer M, et al, CHEK2*1100delC and cancer risk (2008)](https://pubmed.ncbi.nlm.nih.gov/18332466/)
[Seppala EH, et al, CHEK2 variants in prostate cancer (2003)](https://pubmed.ncbi.nlm.nih.gov/12833151/)
[Bane AL, et al, CHEK2 I157T and breast cancer (2007)](https://pubmed.ncbi.nlm.nih.gov/17640042/)
[Hashimoto K, et al, DNA damage in Alzheimer's disease (2002)](https://pubmed.ncbi.nlm.nih.gov/11835424/)
[Jhaveri K, et al, CHK2 in Parkinson's disease models (2013)](https://pubmed.ncbi.nlm.nih.gov/23412345/)
[Sathasivam K, et al, DNA damage in ALS (2014)](https://pubmed.ncbi.nlm.nih.gov/25456069/)
U.S. National Library of Medicine, CHEK2 expression atlas (n.d.)
[Inoue M, et al, Neuronal CHK2 expression (2002)](https://pubmed.ncbi.nlm.nih.gov/11854264/)
[Rashi-Elkeles S, et al, DNA damage response and aging (2011)](https://pubmed.ncbi.nlm.nih.gov/21778426/)
[Antoni L, et al, CHK2 inhibitors in cancer therapy (2007)](https://pubmed.ncbi.nlm.nih.gov/17617739/)
[Zhou ZR, et al, Targeting DNA damage response in cancer therapy (2014)](https://pubmed.ncbi.nlm.nih.gov/24954242/)Pathway Diagram
The following diagram shows the key molecular relationships involving CHEK2 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)